News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Pegcetacoplan Superior to Eculizumab for Paroxysmal Nocturnal Hemoglobinuria

Original Publication Date
Article Source
External Web Content
Pegcetacoplan was superior to eculizumab in improving outcomes in patients with paroxysmal nocturnal hemoglobinuria (PNH) according to a recent study published in the New England Journal of Medicine. PNH is a rare, acquired hematologic disease that causes fatigue, increased risk…

Blood cancer risk higher than expected in kids with Down syndrome

Original Publication Date
Article Source
External Web Content
New York, April 7 The risks of acute myeloid leukaemia (AML)—a type of blood cancer—in children with Down syndrome is stronger than expected, according to a new study. The study led by researchers from the University of Chicago, Davis Health and San Francisco, examined medical…

Myeloablative vs. Reduced Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes—Long Term Follow up of BMT CTN 0901 Clinical Trial

Original Publication Date
Article Source
External Web Content
Abstract Background : Several prospective randomized trials comparing conditioning intensity prior to allogeneic hematopoietic cell transplantation (HCT) have been performed with conflicting results. While reduced intensity conditioning (RIC) leads to lower treatment-related…

Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: a prospective study of feasibility, safety, and healthcare resource use

Original Publication Date
Article Source
External Web Content
Abstract Background We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period. Methods A total of 20 eligible patients were treated…

Scientists discover two unique subtypes of a prominent mutation in patients with AML

Original Publication Date
Article Source
External Web Content
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) – called NPM1 – that could help predict survival and improve treatment response for patients whose leukemic cells bear…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families